Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.53 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932685 | 0.89 | F7 (0.47) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL362393 | 0.86 | F7 (0.52) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL28749718 | 0.84 | ALDH1A1 (0.47) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL1354543 | 0.84 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL1354541 | 0.84 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL29658816 | 0.84 | SMN1; SMN2 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL3135737 | 0.84 | SMN1; SMN2 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL1533618 | 0.83 | SRC (0.58) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17233924 | 0.82 | CYP17A1 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL10534069 | 0.82 | F7 (0.48) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | claimed |
| CN-101796055-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2013-09-04 | — | — | CN | disclosed |
| CN-100415720-C | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN BREWERY (JP) | 2008-09-03 | — | — | CN | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | F7 4082/4885F3 418/4885SARM1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.